About Mitogen-activated protein kinase 1
Mitogen-activated protein kinase 1 (MAPK1) is a protein
from Homo sapiens identified by UniProt accession
P28482, 360 residues long.
MolForge cross-references it against 0 known binders and
703 disease associations.
Target properties
| Protein name | Mitogen-activated protein kinase 1 |
| UniProt accession | P28482 |
| Gene | MAPK1 |
| Organism | Homo sapiens |
| Length | 360 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (703)
Diseases linked to this target (Open Targets).
- Noonan syndrome · score 0.67
- cancer · score 0.62
- Atypical behavior · score 0.61
- Intellectual disability · score 0.60
- cervical squamous cell carcinoma · score 0.52
- Specific learning disability · score 0.51
- Abnormal facial shape · score 0.51
- hypertrophic cardiomyopathy · score 0.51
- Costello syndrome · score 0.50
- head and neck squamous cell carcinoma · score 0.49
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P28482-F1 | alphafold | PREDICTED | 90.37 | — |
Amino-acid sequence (360 residues)
MAAAAAAGAG PEMVRGQVFD VGPRYTNLSY IGEGAYGMVC SAYDNVNKVR VAIKKISPFE HQTYCQRTLR EIKILLRFRH ENIIGINDII RAPTIEQMKD VYIVQDLMET DLYKLLKTQH LSNDHICYFL YQILRGLKYI HSANVLHRDL KPSNLLLNTT CDLKICDFGL ARVADPDHDH TGFLTEYVAT RWYRAPEIML NSKGYTKSID IWSVGCILAE MLSNRPIFPG KHYLDQLNHI LGILGSPSQE DLNCIINLKA RNYLLSLPHK NKVPWNRLFP NADSKALDLL DKMLTFNPHK RIEVEQALAH PYLEQYYDPS DEPIAEAPFK FDMELDDLPK EKLKELIFEE TARFQPGYRS
Explore Mitogen-activated protein kinase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets